Meeting
2014 ASCO Annual Meeting
Gene expression profile test (GEP) prediction of metastasis-free (MFS) and overall survival (OS) in a cohort of cutaneous melanoma (CM) patients undergoing sentinel lymph node biopsy (SLNB).
Authors
David H. Lawson
Emory University School of Medicine, Atlanta, GA
David H. Lawson , Maria C. Russell , Jeff Wilkinson , Gilchrist L. Jackson , Anthony Greisinger , Rodale N Amaria , Rene Gonzalez , Stephen Lyle , Clare Johnson , Kristen M. Oelschlager , John F Stone , Derek Maetzold , Robert W. Cook , Laura Ferris , Keith A. Delman , Pedram Gerami
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9022)
DOI
10.1200/jco.2014.32.15_suppl.9022
Abstract #
9022
Poster Bd #
37
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Performance of a 31-gene expression profile (GEP) test for metastatic risk prediction in cutaneous melanomas (CM) of the head and neck.
First Author: John T. Vetto
Poster
2016 ASCO Annual Meeting
Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients.
First Author: Jonathan S. Zager
Poster
2022 ASCO Annual Meeting
Use of Merlin Assay to identify patients with a low-risk for SN metastasis in a prospective multicenter Dutch study of a primary melanoma gene-signature (CP-GEP model) to predict sentinel node status during COVID-19.
First Author: Robert Stassen
Poster
2022 ASCO Annual Meeting
MERLIN_001: A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of patients with SN-negative melanoma.
First Author: Tina J. Hieken